目的 探究鹽酸埃克替尼對表皮生長因子受體（EGFR）突變陽性非小細胞肺癌腦轉移的近期效果。方法 選取于南陽市中心醫(yī)院腫瘤醫(yī)院收治的EGFR突變陽性非小細胞肺癌腦轉移患者共60例，所有患者均接受鹽酸?？颂婺崞诜委?，125 mg/次，3次/d。回顧性分析其近期效果。結果 患者中位無進展生存期為12.6個月（95% CI 11.85~14.42）。所有患者均接受療效評估，其中部分緩解（PR）23例，穩(wěn)定（SD）37例，EGFR突變非小細胞肺癌（NSCLC）腦轉移患者的有效率（ORR）為38.33%，疾病控制率（DCR）為100%。患者的治療史、基因突變情況、性別以及吸煙與否與治療無進展生存期（PFS）均無顯著相關性（P>0.05）；患者的治療史，性別與是否吸煙與ORR無顯著相關性（P>0.05），而患者的基因突變情況與ORR顯著相關（P<0.05）。不良反應發(fā)生情況：皮疹共出現5例，皮膚干燥9例，腹瀉3例，肝功能異常2例。結論 鹽酸?？颂婺嶂委烢GFR突變陽性非小細胞肺癌腦轉移療效顯著，臨床應用前景光明。

Objective To explore the short-term effect of icotinib hydrochloride on EGFR mutation positive brain metastases from non-small cell lung cancer. Methods A total of 60 patients with brain metastasis from non-small cell lung cancer with EGFR mutation positive in Nanyang Central Hospital, Oncology Hospital were selected. All patients were treated with Icotinib Hydrochloride Tablets, 125 mg/time, orally, three times daily. Retrospective analysis of its short-term effect. Results The median PFS was 12.6 months (95%CI 11.85 to 14.42). All patients were evaluated for efficacy with 23 cases of PR and 37 cases of SD. The treatment of ORR in NSCLC were 38.33%, and DCR were 100%. There was no significant correlation between the history of treatment, gene mutation, sex and smoking history with PFS (P>0.05). There was no significant correlation between the history of treatment, sex, gender and whether smoking with ORR (P>0.05), and the gene mutation of patients was significantly correlated with ORR (P<0.05). Adverse reactions occurred in 5 cases of rash, 9 cases of skin drying, 3 cases of diarrhea, and 2 cases of abnormal liver function. Conclusion Icotinib hydrochloride treatment of EGFR mutation positive brain metastases of NSCLC has significant effect, with promising clinical application.